Ocata Therapeutics Inc., of Marlborough, Mass., said it plans to offer 10 million shares of its common stock in an underwritten public offering under an existing shelf registration statement. As part of this offering, the company intends to grant the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock. The offering has not yet been priced.